In patients with secondary ALL, significant correlations between the therapy response, the sensitivity of tumor cells to daunorubicin (r = 1.0), and the expression of the progenitor marker, CD45 (r = 0.50), which is one of the stratification markers of ALL [55], were found (Figure 3B). This evidence concerns the gene PTPRC and neoplasm.